AstraZeneca profit jumps as cancer drug sales grow

Profit after tax rose to $10.2 billion in 2025 from $7.0 billion a year earlier, AstraZeneca said in a statement. Revenue increased nine percent to $58.7 billion, boosted by a rise in cancer drug sales. "In 2025, we saw strong commercial performance across our therapy areas and excellent pipeline delivery," chief executive Pascal Soriot said in an earnings statement. "The momentum across our company is continuing in 2026," he added. Soriot later told reporters he was "very confident" the company...